Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in European Patients With Neuroendocrine Tumours
NCT04579679Phase 2Terminated
- Sponsor
- HUTCHMED
- Start
- Aug 2021
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 2 trial of surufatinib in Neuroendocrine Neoplasm (NEN), sponsored by HUTCHMED. Started Aug 2021; status: terminated.
02
Drugs
surufatinib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04579679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04579679.